AskBio Phase II heart failure trial of umiposgene parvec win

German pharma major Bayer’s (BAYN: DE) wholly-owned and independently operated subsidiary AskBio has announced the presentation of baseline participant characteristics from GenePHIT, one of the largest randomized gene therapy trials conducted in heart failure to date.

This presentation highlights the trial’s successful enrollment and further validates that multinational gene therapy trials of this size can be conducted. The Phase II clinical trial is evaluating the investigational one-time gene therapy umiposgene parvec (AB-1002) for its potential to improve cardiac function. Baseline characteristics from the trial are being presented at the European Society of Cardiology (ESC) Congress, which takes place in Munich, Germany, August 28–31, 2026.